MILWAUKEE, Wis., Oct. 29, 2018 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced today that Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System xc-, at the annual Society for Neuroscience meeting taking place November 3-7, 2018 in San Diego, California.
This presentation is scheduled for:
Date: Wednesday, November 7, 2018
Title: SXC-2023, a Potential Therapeutic for Various CNS Disorders, is Safe and Well-Tolerated in Phase 1 Clinical Studies
Poster Number: 684.06
About Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders. Promentis' drug development efforts are focused on a unique approach to address imbalances in glutamatergic neurotransmission and oxidative stress. The Company's first indication is trichotillomania, a highly prevalent disorder for which there is no approved therapy, and for which there are no other known treatments in development. For more information regarding trichotillomania, see http://www.promentispharma.com/technology/trichotillomania/
For further information, please contact:
Promentis Pharmaceuticals
Chad E. Beyer, PhD
(e) cbeyer@promentispharma.com
Media Contact:
Tiberend Strategic Advisors, Inc.
Janine McCargo
(t) 646-604-5150
(e) jmccargo@tiberend.com
SOURCE Promentis Pharmaceuticals, Inc.
